Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
- None.
- None.
Insights
The revocation of marketing authorizations for generic versions of TECFIDERA® by the European Commission represents a significant development for Biogen Inc. This decision effectively eliminates immediate generic competition within the EU, allowing Biogen to maintain its market exclusivity until February 2025. Exclusivity is a critical driver of profitability in the pharmaceutical industry, as it prevents price erosion from generic alternatives.
The impact on Biogen's financial outlook is likely positive, as the company can continue to capitalize on the full pricing potential of TECFIDERA® without competition. This could lead to an upward revision of revenue forecasts and potentially strengthen investor confidence in Biogen's near-term revenue streams. However, investors should be aware that such regulatory decisions can invite further legal challenges from generic manufacturers, which could introduce volatility to Biogen's stock.
In the longer term, Biogen's commitment to defending its market protection rights underscores the strategic importance of TECFIDERA® within its portfolio. The firm's ability to secure supply for the entire European market also indicates robust operational capabilities. Nonetheless, reliance on a single product for a significant portion of revenue can be risky and Biogen's future growth will likely depend on its ability to innovate and diversify its product offerings post-2025.
From an IP perspective, the European Commission's decision affirms the strength of Biogen's data protection rights for TECFIDERA®. Data exclusivity is a form of IP rights that prevents competitors from using the original manufacturer's clinical trial data to obtain marketing approval for generic versions. The confirmation of Biogen's entitlement to full data and marketing protection until 2025 is a testament to the company's strategic IP management and its ability to leverage legal avenues to sustain its market position.
For stakeholders, this development emphasizes the importance of robust IP strategies in the pharmaceutical sector. The outcome may prompt competitors to reassess their approach to challenging market exclusivities and could lead to increased investment in R&D to develop alternative therapies. While this decision is favorable for Biogen, it could also raise concerns regarding the availability and affordability of treatments for multiple sclerosis patients in the EU, as generics typically offer more cost-effective options.
Companies within the pharmaceutical industry should note the precedent set by this case, which highlights the potential for data exclusivity to extend market protection beyond patent expiration. This could influence future investment decisions and the structuring of clinical trials to maximize data protection periods.
The revocation of generic marketing authorizations has broader implications for healthcare policy and access to medicines. While this decision benefits Biogen by safeguarding its revenue from TECFIDERA®, it may have adverse effects on healthcare systems and patients. Exclusivity periods for drugs can lead to higher costs for payers, including government health programs and patients, due to the lack of lower-priced generic alternatives.
Policy makers and healthcare providers may face increased pressure to manage budgets as the cost of multiple sclerosis treatments remains high. This could potentially lead to difficult decisions regarding the allocation of resources and prioritization of treatments. On the other hand, the protection of innovation is essential for the development of new and improved therapies and this decision reinforces the legal framework that incentivizes pharmaceutical research and development.
It is important for healthcare systems to strike a balance between encouraging pharmaceutical innovation and ensuring patient access to affordable medicines. The outcome of Biogen's legal action to defend its market protection rights could set a precedent for future cases and influence healthcare policy regarding drug pricing and reimbursement.
CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.
In reaching this decision, the European Commission affirmed that Biogen is entitled to full data protection and marketing protection for TECFIDERA. Biogen welcomes the actions of the European Commission, which confirm the laws governing data exclusivity and marketing protection. Those laws are essential to protecting innovation.
TECFIDERA is entitled to marketing protection until February 3, 2025, and is the only dimethyl fumarate treatment for multiple sclerosis that may be lawfully placed on the market for sale in the EU until that date. Biogen has initiated legal action to defend its market protection rights. Biogen has sufficient supply of TECFIDERA to supply the entire European market.
About Biogen
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, two co-developed treatments to address a defining pathology of Alzheimer’s disease, the first treatment to target a genetic form of ALS, the first oral treatment approved for postpartum depression, and the first approved treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements about the Biogen’s supply of Tecfidera; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs; and risks and uncertainties associated with drug development and commercialization, including data exclusivity and marketing protection. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates; actual timing and content of submissions to and decisions made by the regulatory authorities; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; third party collaboration risks; and the direct and indirect impacts of the ongoing COVID-19 pandemic on Biogen's business, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.
| MEDIA CONTACT: Biogen Jack Cox + 1 781 464 3260 public.affairs@biogen.com | INVESTOR CONTACT: Biogen Chuck Triano +1 781 464 2442 IR@biogen.com | |
FAQ
What did the European Commission announce regarding Biogen Inc. (Nasdaq: BIIB)?
What is the marketing protection period for TECFIDERA®?
What legal action is Biogen Inc. (Nasdaq: BIIB) taking?
Does Biogen Inc. (Nasdaq: BIIB) have sufficient supply of TECFIDERA®?
What laws did the European Commission affirm in support of Biogen Inc. (Nasdaq: BIIB)?
Who are the companies whose marketing authorizations for generic versions of TECFIDERA® were revoked?
